Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Feb 25;17(2):e0263678. doi: 10.1371/journal.pone.0263678

Whole genome sequence analysis showing unique SARS-CoV-2 lineages of B.1.524 and AU.2 in Malaysia

Ummu Afeera Zainulabid 1,2,#, Aini Syahida Mat Yassim 3,#, Mushtaq Hussain 4,*, Ayesha Aslam 4, Sharmeen Nellisa Soffian 1, Mohamad Shafiq Mohd Ibrahim 5, Norhidayah Kamarudin 6, Mohd Nazli Kamarulzaman 7, How Soon Hin 2,*, Hajar Fauzan Ahmad 1,8,*
Editor: Ahmed S Abdel-Moneim9
PMCID: PMC8880882  PMID: 35213571

Abstract

SARS-CoV-2 has spread throughout the world since its discovery in China, and Malaysia is no exception. WGS has been a crucial approach in studying the evolution and genetic diversity of SARS-CoV-2 in the ongoing pandemic. Despite considerable number of SARS-CoV-2 genome sequences have been submitted to GISAID and NCBI databases, there is still scarcity of data from Malaysia. This study aims to report new Malaysian lineages of the virus, responsible for the sustained spikes in COVID-19 cases during the third wave of the pandemic. Patients with nasopharyngeal and/or oropharyngeal swabs confirmed COVID-19 positive by real-time RT-PCR with CT value < 25 were chosen for WGS. The selected SARS-CoV-2 isolates were then sequenced, characterized and analyzed along with 986 sequences of the dominant lineages of D614G variants currently circulating throughout Malaysia. The prevalence of clade GH and G formed strong ground for the presence of two Malaysian lineages of AU.2 and B.1.524 that has caused sustained spikes of cases in the country. Statistical analysis on the association of gender and age group with Malaysian lineages revealed a significant association (p <0.05). Phylogenetic analysis revealed dispersion of 41 lineages, of these, 22 lineages are still active. Mutational analysis showed presence of unique G1223C missense mutation in transmembrane domain of the spike protein. For better understanding of the SARS-CoV-2 evolution in Malaysia especially with reference to the reported lineages, large scale studies based on WGS are warranted.

Introduction

The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Wuhan, China in December 2019 resulted in an unprecedented global outbreak and soon recognized as pandemic, referred to as COVID-19 [14]. SARS-CoV-2 actively propagates in lungs as a primary site of infection. This active propagation leads to the storm of inflammatory cytokines that if not curtailed advances the pathology of the disease [5]. By November 2021, more than 260 million confirmed cases of COVID-19, with over 5 million deaths have been reported by the World Health Organization (WHO) [6]. By the same date, the cumulative number of confirmed cases of COVID-19 in Malaysia has reached over 2.6 million, of which over 30,000 died from the disease. The daily number of confirmed cases of COVID-19 has continued to soar with more than 10,000 cases per day since July, 2021, however at present, due to the mass vaccination drive, the cases are dwindling with encouraging pace [7]. Malaysia is facing a much tougher task in curbing the COVID-19 pandemic in its third wave which began on September 8, 2020 due to the Benteng LD cluster in Sabah [8]. Since then, the highest lineage contributor during the third wave of pandemic appeared to be B.1.524, with D614G and A701V mutations in the spike protein of the virus [9].

The WHO defined SARS-CoV-2 Variant of Concerns (VOCs) as variants with clear evidence indicating significant impact on transmissibility, severity (including hospitalizations or death) and/or immunity due to significant reduction in neutralization by antibodies generated during previous infection or by vaccination. This in total may impact the epidemiological landscape of the virus [10,11]. Whereas Variant of Interests (VOIs) are variants with specific genetic markers that have been associated with changes in receptor binding regions of the virus, reduced neutralization by antibodies generated due to previous infection or by vaccination, reduced efficacy of treatments, potential diagnostic impact, or predicted increase in transmissibility or disease severity, but warrant continuous monitoring and further investigations [12]. The SARS-CoV-2 VOC, α (B.1.1.7) was first detected in Malaysia in February 2021 followed by then considered VOI, η (B.1.525) VOC, β (B.1.351) in March this year. Whereas, SARS-CoV-2 VOC, Δ (B.1.617.2) and then considered VOI, κ (B.1.617.1), were first detected in June 2021 in Peninsular Malaysia [13]. In Sarawak, the first Δ variant was detected on June 2021, along with then recognized VOI, θ (P.3) in 2021 [14].

Of interest, all of the VOCs and VOIs detected in Malaysia harbour D614G mutation in their spike protein [15,16]. Until recently, 90.30% of all COVID-19 infection in Malaysia has been due to the D614G variant, and this mutation is present in all the new emerging variants [15]. As a result of positive natural selection, it was found that D614G increases the infectivity, viral fitness, transmission rate and efficiency of cellular entry for the SARS-CoV-2 virus across a broad range of human cell types [9,1723]. Nevertheless, D614G mutation alone has not been shown to cause higher COVID-19 mortality or clinical severity, or alter the efficiency of the current laboratory diagnostic, therapeutics, vaccines or public health prevention strategies [11,24]. Therefore, in this study, we analyzed the dominant lineages of D614G variants currently circulating in Malaysia using whole genome sequences of the Malaysian SARS-CoV-2 deposited to the Global Initiative on Sharing All Influenza Data (GISAID) database. This study reports new Malaysian lineages that are responsible in causing sustained spikes in COVID-19 cases throughout the third wave of the pandemic in Malaysia. We have also investigated the divergence of the D614G variant of the Pahang SARS-CoV-2 isolates and explored its possible origin. Finally, we have computationally predicted possible effects of the G1223C mutation, observed in this study, resided in the transmembrane domain of the spike protein and uniquely detected in SARS-CoV-2 from Pahang, Malaysia.

Materials and methods

Sample selection

Nasopharyngeal and oropharyngeal swab test results from over 1000 patients that were confirmed positive for SARS-CoV-2 through real-time reverse transcriptase-PCR (real-time RT-PCR) at the Sultan Ahmad Shah Medical Centre were initially taken into consideration. Out of these only 10 patients were selected for whole genome sequencing of the virus on the basis of CT value <25 and when the total extracted genomic RNA level was found to be more than 10 ng/μl. Ethical approval (IREC 2021–080) for the study was obtained from IIUM Research Ethics Committee.

RNAs extraction

Total genomic RNA was extracted using Maxwell HT simplyRNA kit (Promega, USA) following manufacturer guidelines.

Next-generation sequencing of the full-length viral genome

Next-generation sequencing (NGS) library was constructed after amplifying full length genome using synthesized cDNA from SuperScriptIV (ThermoFisher Scientific, USA) with some modifications [25,26]. Briefly, 5 μl of the cDNA was used as template for multiplex PCR using Q5 polymerase (NEB, USA) as well as the Artic v3 primer pools during library preparation. The constructed library was then sequenced on an iSeq 100 System (Illumina, USA) (with run configuration of 1 × 300 bp).

Sequence analysis

The SARS-CoV-2 genome was reconstructed from the raw reads using a combination of several bioinformatic tools enlisted in https://github.com/CDCgov/SARS-CoV-2_Sequencing/tree/master/protocols/BFX-UT_ARTIC_Illumina. Genome sequences from other studies related to humans and animal coronaviruses were mined from the GISAID (https://www.gisaid.org) and NCBI GenBank (https://www.ncbi.nlm.nih.gov/genbank/).

Public database SARS-CoV-2 genome analysis

To study the dominant lineages and D614G frequency, a total of 1356 complete genome sequences of SARS-CoV-2 of Malaysian origin, submitted to GISAID from March 1, 2020 to July 19, 2021 were retrieved (S1 Table). Sequences were selected based on completion of the genome with minimum number of unresolved nucleotides. Restraining the selection from 1356 to 986 sequences (S1 File). Analysis of lineage distribution and clade frequency were performed manually by using Pivot table in Microsoft Excel. Real-time Malaysia SARS-CoV-2 Genomics Surveillance updates were monitored via (https://bit.ly/2UEFFGt).

The first virus from each lineage with D614G mutation in spike protein was extracted using patient’s status metadata downloaded from GISAID on July 19, 2021. To do this, 1356 viruses were analysed manually using Pivot table and the dates were filtered to months and year in Microsoft Excel. The lineage description was classified according to the PANGO Lineage List (https://cov-lineages.org/lineage_list.html).

Phylogenetic analysis

A total of selected 986 complete whole genome sequences of Malaysian variants with D614G mutation were retrieved from GISAID database (S1 Table; S1 File). A complete genome of Wuhan-Hu-1 (NC_045512) was downloaded from GenBank (https://www.ncbi.nlm.nih.gov/sars-cov-2/) for outgroup. The multiple sequence alignment was performed using Clustal Omega [27] and observed in BioEdit [28] and finalized using MEGA XI [29].

Evolutionary analysis was conducted in MEGA XI by reconstructing bootstrap consensus tree of sequences employing Neighbor-Joining (NJ) method with 1000 bootstrap replicates to represent the evolutionary history of the taxa analyzed [30]. Branches corresponding partitions that are reproduced in less than 50% bootstrap replicates were collapsed. The evolutionary distances were computed using the Kimura 2-parameter method and are in the units of the number of base substitutions per site. The rate variation among sites was modelled employing gamma distribution (shape parameter = 1). All ambiguous positions were removed for each sequence pair employing complete deletion option).

Mutation analysis

Mutation analyses were carried out using Nextclade v.1.5.2, a web-based analysis server (https://clades.nextstrain.org) by comparing against a wild-type of Wuhan-Hu-1 (NC_045512.2).

To evaluate the effect of mutations, a 3D structure model of wild-type spike protein (YP_009724390.1) was first generated using SWISS-model based on the most fitted protein template PDB ID: 6XR8 covering 14–1162 amino acids of the protein. For analyzing the effect of amino acid substitution in the TM domain, a 3D structure, PDB ID: 7LC8 (SARS-CoV-2 Spike protein TM domain) was used. Both 3D structure model of YP_009724390.1 and 7LC8 were uploaded to mCSM-PPI2 server [31]. Next, the potential pathogenic effect of the amino acid substitution on TM domain was investigated by uploading a 3D structure of TM domain, PDB ID: 7LC8 and TM domain amino acid sequence onto mCSM-membrane [32]. Similarly, Protein Variation Effect Analyzer (PROVEAN) [33] and SNAP 2 tools [34]; the web-based servers for predicting the effect of mutations were also used for the same purpose. The servers predicted the consequence of amino acid mutation to be whether benign or pathogenic, deleterious or neutral, effect or neutral, respectively.

Statistical analysis

Data were presented as count and percentage. Chi-square test was carried out using IBM SPSS v25.0 to test the statistical significance for association of gender, patient status and age groups with Malaysian lineages. All level of significances were set at p < 0.05.

Results

Evolution of D614G variant of SARS-CoV-2 in the Malaysian population

Of the 1,502 SARS-CoV-2 complete genomes deposited to GISAID database, 1,356 contained spike D614G mutation in their genomes. To better characterize the local distribution of lineages that may contribute to the constant increase in COVID-19 cases in Malaysia, Fig 1 summarizes the distribution of the D614G variant lineages throughout the country since it was first detected on March 21, 2020. Based on the GISAID database analysis, there were 41 lineages of D614G variant dispersed throughout Malaysia. Lineage B.1.524 (n = 419) and AU.2 (n = 311) appeared to have caused significant transmission of the virus locally compared to Variant of Concern (VOC) α B.1.1.7 (n = 11), β (B.1.351(n = 161), B.1.351.3 (n = 2)) and Δ B.1.617.2 (n = 58); Variant of Interest (VOI) η B.1.525 (n = 3), κ B.1.617.1 (n = 3), as well as lineages currently designated alerts for further monitoring, such as P.2 (n = 1), P.3 (n = 10), B.1.466.2 (n = 70), B.1.214.2 (n = 1).

Fig 1. SARS-CoV-2 D614G variant lineages and clades distribution in Malaysia.

Fig 1

(A) Distribution of lineages of SARS-CoV-2 D614G variant from Malaysia deposited in GISAID until July 5, 2021 (n = 1356). (B) Donut diagram showing clade distribution of D614G variants from Malaysia deposited in GISAID until July 19, 2021 (C) Lineages clustered in clade GH (D) Lineages clustered in clade G.

Next, we investigated the frequency of D614G variant clades circulating in Malaysia until July 2021. It appeared that of the six D614G variant clades (GH, G, GR, GRY, O and GV), GH makes up the largest clade with 760 of genomes from different lineages (Fig 1B). Further analysis of clade GH shows lineage AU.2 had appeared most often in the transmission of the disease (Fig 1C) followed by clade G, in which lineage B.1.524 seems to be the highest contributor in the local transmission of COVID-19 (Fig 1D).

Our findings on genomic surveillance in depicting local transmission and evolution of the D614G variant revealed that two of the variants had emerged locally: B.1.524, and AU.2, (S2 Table, highlighted in grey) here referred to as Malaysian lineages. Of these two, B.1.524, which was first detected in September, 2020, had silently caused the largest local transmission of the D614G variant in Malaysia (n = 419), followed by AU.2 (n = 311).

Furthermore, segregating the genomes analysis based on years, we found a clear pattern of lineage distribution which demonstrates how the major lineages disperse throughout Malaysia in 2020 and 2021 (S1 Fig). While the B.1.524 may have contributed heavily to the active spreading of D614G lineage locally, the data suggest that the AU.2 lineage, which was first detected on January 3, 2021 (S2 Table, highlighted grey), is currently taking its place as the major D614G variant contributor in spreading the disease. Using the patients’ status metadata in S1 Table, we suggest that AU.2 might have originated from Sarawak, however, the origin of B.1.524 remains unknown.

Next we analysed the association of gender, patient status and age group with Malaysian lineages B.1.524 and AU.2 (Table 1). Significant association was observed between lineages and both gender and age groups. Males have been found slightly more prone to be infected by the lineage, B.1.524 (p = 0.049). It was also observed there is a significant association between lineages and age groups (p = 0.038). However, there was no significant association observed between lineage and patient’s status in term of disease severity.

Table 1. The distribution of the lineages between gender, patient status and age groups.

Lineage, n(%) Total, n(%) C2 p-value
AU.2 (GH) B.1.524 (G)
Gender Male 134 (37.9) 220 (62.1) 354 (100) 3.862 0.049
Female 132 (45.5) 158 (54.5) 290 (100)
Patient Status Deceased 0 3 (100) 3 (100) 1.541 0.463
Hospitalized 0 6 (100) 6 (100)
Live 36 (14.7) 209 (85.3) 245 (100)
Age Groups 0–14 years 27 (50.9) 26 (49.1) 53 (100) 6.542 0.038
15–64 years 190 (40.7) 277 (59.3) 467 (100)
>64 years 43 (54.4) 36 (45.6) 79 (100)

Origin of the massive spread of COVID-19 cases in Pahang

To infer the origin of the D614G variant that was responsible in causing widespread COVID-19 infections in Pahang this year, we built a NJ phylogenetic tree using complete genomes of D614G variant of Malaysian origin retrieved from GISAID along with sequence data from this study. The collection dates were restricted from January 1, 2021 to July 2021 (n = 986). Based on Nextstrain clade analysis, there were 22 SARS-CoV-2 lineages actively dispersed in Malaysia in 2021, divided into 10 clades (Fig 2A; S2 File). Genomes of Pahang SARS-CoV-2 D614G variants were found congregrated into African, Indonesian and Malaysian lineages (Fig 2B and 2C).

Fig 2. Phylogenetic tree of 986 complete genomes of Malaysia SARS-CoV-2 D614G variants in 2021.

Fig 2

(A) Nextstrain clade distribution (inset) of 986 complete genomes of Malaysia SARS-CoV-2 D614G variant (filled circles) (B) Nextstrain clade and lineage distribution (inset) of the Pahang SARS-CoV-2 D614G variants (filled circle). Please see S2 File for the fully annotated tree (C) Phylogenetic relationship of the Pahang SARS-CoV-2 D614G variants (blue branches) with the selected neighbouring representatives (in Nextstrain clade tree) of SARS-CoV-2 genome sequences of African (green branches), Indonesian (red branches) and Malaysian lineages (yellow branches). The tree is reconstructed by Neighbor Joining (NJ) method with 1000 bootstrap replicates. Bootstrap values are indicated at nodes. Note the strong bootstrap support (99%-100%) at the common node of each lineage. In parenthesis city of the subjects are mentioned where arrow heads represent direction of traveling.

In order to further resolve the phylogenetic analyses of the D614G variant actively spreading in Pahang. A separate phylogenetic analysis was conducted with neigbouring representative sequences (in Nextstrain clade tree) of African, Indonesian and Malaysian lineages (Fig 2C) with Pahang SARS-CoV-2 D614G variants genomes. Topologically, the tree showed that EPI_ISL_2622079/SAMN19778017 (Kuala Lumpur, April 2021) clustered (100% bootstrap values) with B.1.462 (Indonesian lineage) with close relationship with EPI_ISL_2342564 (April 2021) and EPI_ISL_2090887 (May 2021), which were originated in Selangor (Fig 2C). Additionally, EPI_ISL_2622079 isolate was taken from subject having travel history from Kuala Lumpur to Pahang indicating interstate transmission of the Indonesian lineage of SARS-CoV-2 to Pahang (Fig 2B and 2C; S2 File). Whereas, EPI_ISL_2622089/ SAMN19778020 (Pahang, May 2021), EPI_ISL_2621677/SAMN19778012 (Pahang, April 2021) EPI_ISL_2622006/SAMN19778019 (Pahang, April 2021), EPI_ISL_2622007/SAMN19778013 (Pahang, April 2021), EPI_ISL_2622046/ SAMN19778014 (Kelantan, April 2021), EPI_ISL_2622047/SAMN19778015 (Kelantan, April 2021), EPI_ISL_2622088/SAMN19778018 (Kelantan, April 2021), clustered with β B.1.351 (African lineage) with 100% bootstrap values. It is important to note EPI_ISL_2622046 (Kelantan, April 2021), EPI_ISL_2622047 (Kelantan, April 2021), EPI_ISL_2622088 (Kelantan, April 2021) isolates were taken form subjects who had travelling history from Kelantan to Pahang and all three resided in different subclades of African lineage (Fig 2C) potentially indicating interstate transmisson of the virus. In comparison EPI_ISL_2828708/SAMN19778011 (Pahang, April 2021) and EPI_ISL_2622045/SAMN19778016 (Pahang, April 2021), clustered (99% bootstrap values) with B.1.524 (Fig 2C), referred to as Malaysian lineage. All sequences are made avaiable at https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP324679.

Mutations in spike protein of Malaysian lineages

Total 419 complete genomes of B.1.524 and 311 complete genomes of AU.2 were uploaded to Nextclade v.1.5.2 (https://clades.nextstrain.org) to analyse dominant mutations occur in spike protein of Malaysian lineages. In addition to D614G mutation, B.1.524 also carries A701V mutation in the spike protein. Whereas, AU.2 carries a mutation at positions N439K, P681R and G1251V.

Amino acid mutations in spike protein of the Pahang- D614G variant SARS-CoV-2

Using Nextclade v.1.5.2 for clade assignment, mutation calling and sequence quality checks (https://clades.nextstrain.org), 1356 complete genomes of the D614G variant were analysed for sequence quality and mutations. Of that, 986 complete genomes passed Nextclade’s sequence quality control highlighting different mutations in the spike protein. Our analysis revealed that all of Pahang’s SARS-CoV-2 isolates has a unique substitution mutation of Glycine (G) to Cysteine (C) at position 1223 (G1223C) which was not found in the other 976 genomes (Fig 3).

Fig 3. Nonsynonymous mutations in the spike protein of Malaysian SARS-CoV-2 D614G variants.

Fig 3

(A) Nextstrain clade mutation analysis (vertical bars) of 986 Malaysian SARS-CoV-2 genomes, where Pahang SARS-CoV-2 D614G variants are highlighted in the box. Note the presence of unique mutation at G1223C in only Pahang SARS-CoV-2 D614G variants (B) Enlarged view of the Pahang SARS-CoV-2 D614G variants box where amino acid substitutions are annotated in the different regions of spike protein, schematically represented at bottom. Horizontal rows are correspondingly annotated with sample code, GISAID accession numbers and lineages.

The impact analysis of single-point mutations on protein-protein interaction binding affinity was performed using mCSM-PPI2. The result of the analysis are summarized in Table 2. To do this, a 3D structural model of wild type spike protein (YP_0097243901) was first generated through SWISS MODEL using a protein template model of 6XR8 (distinct conformation states of SARS-CoV-2 spike protein). Of note, mCSM-PPI2 is unable to predict the change in protein interaction affinity in deletions, hence analysis on L241del, L242del and A243del were not included in Table 2. To analyse the impact of G1223C mutation in the TM region of spike protein, a 3D structure model of the SARS-CoV-2 spike protein TM domain (7LC8) was retrieved from RCSB Protein Data Bank and was uploaded to mCSM-PPI2 server. Taken together, the missense mutations, L18F, N501Y, A701V and G1223C seem to have increased the binding affinity of the spike protein, whereas mutations D80A, D215G, K417N, N439K, E484K and A688S had the opposite effect. Unique mutation, G1223C, does not cause significant structural rearrangement of the TM domain, except for the gain in salt bridge between C1223 and G1219 (Fig 4). In addition, PROVEAN and SNAP2 predicted decrease stability due to G1223C mutation in spike protein (Table 3).

Table 2. The predicted effect of missense mutations in the spike protein of Pahang SARS-CoV-2 D614G variants.

Wildtype Residue Number Mutant Distance to Interface MCSM-PPI2-Prediction Affinity
Leu (L) 18 Phe (F) 25.747 0.85 Increase
ASP (D) 80 Ala (A) 24.602 -0.181 Decrease
ASP (D) 215 Gly (G) 23.94 -0.178 Decrease
LYS (K) 417 Asn (N) 3.107 -1.628 Decrease
ASN (N) 439 Lys (K) 7.043 -0.319 Decrease
GLU (E) 484 Lys (K) 13.698 -0.454 Decrease
ASN (N) 501 Tyr (Y) 7.588 0.16 Increase
ALA (A) 688 Ser (S) 26.327 -0.044 Decrease
ALA (A) 701 Tyr (Y) 2.737 0.992 Increase
GLY (G) 1223 Cys (C) 5.489 0.233 Increase

Fig 4. Variations in the intramolecular interactions in transmembrane domain of wild type and mutant spike protein.

Fig 4

Intramolecular molecular interactions (yellow dotted line) in ribbon diagrams of the transmembrane domain of wildtype (G1223) and variant (C1223) SARS-CoV-2 spike protein.

Table 3. Impact prediction of G1223C novel mutation.

Mutation in TM mCSM-membrane (Benign/Pathogenic) PROVEAN (Neutral/Deleterious) SNAP2 (Neutral/Effect)
G1223C Benign Deleterious Effect

Discussion

The first incidence of COVID-19 in Malaysia was reported on January 25, 2020 and was traced back to three Chinese nationals who had direct contact with an infected individual while in Singapore [35]. The local Malaysian authority quickly developed standard guidelines for the management of COVID-19, including the set-up of designated hospitals and screening centers in each state [35]. To date, 2.6 million COVID-19 positive cases are recorded with over 30000 fatalities in the country. Based on earlier report, we found that SARS-CoV-2 variant with D614G mutation had been circulating in Pahang since April 2020 [25] and subsequently found elsewhere throughout Malaysia as the infection continues. For the record, the earliest study on SARS-CoV-2 virus genomes in Malaysia did not found D614G mutation, even the lineage B.6 that contributes profoundly in the second wave in Malaysia did not harbour D614G mutation in the spike protein [36].

Although major concerns have been raised on the emergence of VOC, SARS-CoV-2 β (B.1.351) and SARS-CoV-2 Δ (B.1.617.2), our analysis of SARS-CoV-2 genomes from the Malaysian population reported two different lineages of D614G variant that are actively dispersed locally. To our knowledge, the emergence of lineage B.1.524 was first detected in September last year. The analysis from early 2021 suggests that AU.2 had become the dominant lineage that actively spread in Malaysia in 2021 followed by B.1.524. We observed that AU.2 is closely related to B.1.4662 (Indonesian lineage), as both lineages carry the same amino acid mutations N439K in RBD and P681R in non RBD regions of spike protein. Its presence in Malaysia could be due to the spread of the disease via visitors from Indonesia [37]. Our analysis also suggests, AU.2 is not correlated to B.1.524, as B.1.524 carry different mutations (A701V) in spike protein. Moreover, lineages assignment using pangolin (v2.1.6, https://github.com/cov-lineages/pangolin) demonstrates prevalence of AU.2 and B.1.524 as Malaysia 94.0%, Indonesia 5.0%, United States of America 0.0%, India 0.0%, Singapore 0.0%, and Malaysia 76.0%, Singapore 16.0%, Thailand 3.0%, Philippines 2.0% and India 1.0%.

Of the 41 lineages of D614G variants detected in Malaysia since March 2020, 19 lineages have disappeared, leaving 22 lineages still actively spreading in 2021. During active propagation of the virus, new mutations accumulated in the progeny resulting in the emergence of new viral variants. Non-synonymous substitutions are extremely important since they result in an amino acid change, which may in turn induces structural change [38] and may then later have functional consequences in terms of transmission and pathogenicity [38]. In nations with poor containment capability, it was proven that the SARS-CoV-2 mutant lineage G (D614G) was able to replace earlier lineages more efficiently and was associated with a higher degree of disease severity [39]. Moreover, the emergence of more virulent strains such as included in VOC and VOI that harbored the D614G mutation in spike protein suggests that D614G variant had constantly subjected to positive selection pressure. Consequently, combination of various mutations in spike protein has been observed for increased viral transmission [4042], increased disease severity [43], reduced susceptibility to the monoclonal antibody treatment [44] and reduced neutralization by convalescent and post vaccination sera [4549].

Even though a recent study suggested that the GR was a predominant clade in Asia [50,51], our study found that GH is the major infecting clade in Malaysia, followed by G. To the best of our knowledge, studies related to AU.2 lineage in relation to disease epidemiology and pathology are scarce, however, the VOC, SARS-CoV-2-β (B.1.351) that grouped together with AU.2 clade, was reported to be linked with high disease severity and mortality [52]. Based on these reasons, we anticipated that this lineage may be the cause of high-risk transmission in Malaysia. On the other hand, the Malaysian lineage of B.1.524 is assigned to clade G that commonly associated with mild symptoms or asymptomatic cases [50]. Moreover, another study reported that the infection with clade G was not related with disease severity, and there was no clear indication of enhanced transmissibility despite greater viral loads [50].

Our metadata analysis showed higher (p < 0.05) prevalence among male patient with B.1.524 (G clade) variants, however, large-scale data is needed for further validation. Previous study has also shown that men with COVID-19 have relatively poor prognosis and mortality regardless of age [53] due to potential differences in the immune response between males and females [54]. The disease distribution is significantly higher among adolescent and adult age group in both AU.2 and B.1.524 group (p < 0.05). This could be explained due to presence of comorbidities, immunological senescence and changes in ACE2 receptor [50]. However, our study showed no association between both lineages in relation to disease severity. Here, we anticipate that this may be due to lack of metadata related to the disease severity among Malaysian patients in GISAID database.

Higher infectivity of the SARS-CoV-2 variants is associated with increased in binding affinity between spike protein and ACE2 due to K417N, E484K, N439K and N501Y mutations in the RBD of the spike protein. While N501Y mutation alone enhanced spike RBD-ACE2 affinity [55], combination of K417N, E484K and N501Y mutations in B.1.351 lineage resulted in noticeable conformational changes in RBD when bound to ACE2 [5658]. Although N439K mutation in RBD was first found in already extinct lineage B.1.1.41, a new lineage B.1.258 independently acquired the same amino acid substitution [59]. It is unknown whether B.1.466.2 (also known as Indonesian lineage) and AU.2 of Malaysian lineage, acquired N439K divergently and/or as a result of convergent evolution. Of concern, N439K mutation promotes evasion of antibody-mediated immunity by conferring resistance against several neutralizing monoclonal antibodies and reduces the activity of some polyclonal sera from patients recovered from infection [60]. However, there is no evidence of change in disease severity in a large cohort of patients infected with SARS-CoV-2 harbouring N439K mutation in the spike protein [60]. In addition, A701V mutation, adjacent to the furin cleavage site of spike protein subunit S1 and S2, in B.1.524 of Malaysian lineage was also found in SARS-CoV-2 β (B.1.351) strains and SARS-CoV-2 i B.1.526 (USA) [61]. Our computational analysis predicted A701V with increase protein-protein interaction affinity.

In tracking the distribution of the ten lineages which caused blooming of positive COVID-19 cases in Pahang this year, it appears that all virus collected from Pahang have the same substitution of amino acid at 1233 from Glycine to Cysteine in TM domain of spike protein, not found previously in Malaysia. While the significance of G1223C mutation is still unknown, it is well known that spike protein mediates entry of SARS-CoV-2 into target cells through two steps. First, it involves binding of RBD to its receptor, human ACE2, and is proteolytically activated by human proteases at the S1/S2 boundary. Second, S2 of spike protein including TM domain will undergoes structural change to mediate viral membrane fusion with the targeted cells [62,63]. To date, very little attention have been put on the TM domain involvement in the cellular entry of SARS-CoV-2. Although sequence analysis on TM domain among all coronaviruses spike protein conducted previously [61,63] revealed a high conservation rate in the region, however, extensive mutations in TM domain of SARS-CoV-2 caused incapability of the virus to establish complete membrane fusion process [63]. Highly conserved small amino acids in TM domain of SARS-CoV-2 spike protein (G1219, A1222, G1223, A1226) were initially thought to be important for TM domain oligomerization. However, recent findings showed neither glycine nor alanine in the trimer structure appeared to be important for hydrophobic core formation [64]. Thus, suggesting a possible role of the glycine motif is in a later step of fusion. We believe the effect of G1223C mutation in TM domain deserve further investigations in future functional experiments.

The present study has some limitations. First, the work on WGS in characterizing the circulating variants in Malaysia needed to be underscored systematically by representing Malaysian cases with considerably large sample size. Integration of viral genomics with the epidemiological and modelling data, local transmission chains and regional spread were able to be tracked and audited in real time [65]. This strategy was proven to curb the spread of COVID-19 in developed countries like Australia [66] and New Zealand [65]. Second, lack of metadata in GISAID database hampered the analysis of the impact of the distribution of individual clades on the localized disease epidemiology. We also discovered a plethora of unclear entries that offer very little information about the real source of the samples. All these issues can affect the effectiveness and accuracy of association studies. We therefore advocate for SARS-CoV-2 genomic data providers to provide comprehensive clinical details of deposited sequences, and also encourage genomic database maintainers to be aware of potential errors in incoming samples and to actively support metadata standards. One option may be to entirely disregard samples with suspected metadata issues, however, this may result in considerable reduction of sample size, thereby reducing the power of statistical studies [67].

Conclusion

Herein, we have reported the most prevalent SARS-CoV-2 lineages of B.1.524 and AU.2 that sustained major outbreak of COVID-19 transmission during third wave of infection in Malaysia. Whereby the mutation at G1223C is under reported and further large-scale studies are warranted. Furthermore, the N439K mutation that observed in RBD of AU.2 deserves additional attention and monitoring due to its capability to increase virus infectivity while evading antibody-mediated immunity. Uncontrolled and intensive virus transmission will result in the emergence of new viral variants, which may significantly influence vaccine efficacy and perhaps, disease severity. The continuous emergence of novel SARS-CoV-2 variants highlights the need for public compliance with SOPs and other recommendations, notably mask use, hand cleanliness and physical separation, as well as the necessity to acquire herd immunity through the vaccination program. These measures will aid in slowing viral transmission and reducing the likelihood of new variations emerging in the SARS-CoV-2.

Supporting information

S1 Fig. D614G variant lineage distribution in 2020 and 2021 based on complete genomes deposited to GISAID (Malaysia).

A. The distribution of lineages from March to December, 2020. B. The distribution of lineages from January to July, 2020.

(TIFF)

S1 File. Selected (987) sequences from SARS-CoV-2 D614G variant from Malaysia including Wuhan SARS-CoV-2.

(DOCX)

S2 File. Complete phylogenetic tree in MEGA XI format.

(MTSX)

S1 Table. Collate metadata.

(CSV)

S2 Table. Summary of date and D614G variant virus strains from each lineage first detected in Malaysia.

(PDF)

Acknowledgments

We acknowledge the COVID-19 task forces from Sultan Ahmad Shah Medical Centre @ IIUM and Universiti Malaysia Pahang, Malaysia.

Data Availability

All sequences data are available at https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP324679.

Funding Statement

The authors received funding for this work from the Ministry of Higher Education Malaysia and Sultan Ahmad Shah Medical Centre @ IIUM for supporting this work. Hajar Fauzan Ahmad awarded for FRGS/1/2019/WAB13/UMP/03/1 and Ummu Afeera Zainulabid is Principal Investigator for SRG21-040-0040, respectively. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob. 2020;55(3):105924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–74. doi: 10.1016/S0140-6736(20)30251-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature. 2021. doi: 10.1038/s41586-021-03767-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.COVID-19 Host Genetics Initiative. The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet. 2020;28(6):715. doi: 10.1038/s41431-020-0636-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2.BMJ. 2020;371. [DOI] [PubMed] [Google Scholar]
  • 6.WHO, WHO Coronavirus (COVID-19). Available from: https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19-30-november-2021.
  • 7.COVIDNOW: [Cited at 12th December 2021] Available from: https://covidnow.moh.gov.my/bm/vaccinations/.
  • 8.Rampal L, Liew BS. Malaysia’s third COVID-19 wave-a paradigm shift required. Med J Malaysia. 2021;76(1):1–4. [PubMed] [Google Scholar]
  • 9.Zhang L, Jackson CB, Mou H, Ojha A, Peng H, Quinlan BD, et al. SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020;11(1):1–9. doi: 10.1038/s41467-019-13993-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Walensky RP, Walke HT, Fauci AS. SARS-CoV-2 variants of concern in the United States—Challenges and opportunities. JAMA. 2021;325(11):1037–8. doi: 10.1001/jama.2021.2294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Sanyaolu A, Okorie C, Marinkovic A, Haider N, Abbasi AF, Jaferi U, et al. The emerging SARS-CoV-2 variants of concern. TAI. 2021;8:20499361211024372. doi: 10.1177/20499361211024372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Centers for Disease Control and Prevention. SARS-CoV-2 Variant Classifications and Definitions. In: Centers for Disease Control and Prevention; [Internet]. 2021. [cited 13 Jul 2021] p. COVID-19. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html. [Google Scholar]
  • 13.Salim Syafiqah. Covid-19: Malaysia detects another six variants of concern cases from June 20–22 | The Edge Markets. In: theedgemarkets.com; 2021: https://www.theedgemarkets.com/article/covid19-malaysia-detects-another-six-variants-concern-cases-june-2022. [Google Scholar]
  • 14.DayakDaily. First Covid-19 Delta variant case detected in Kuching on June 18. In: DayakDaily [Internet]. 202. Available from: https://dayakdaily.com/first-covid-19-delta-variant-case-detected-in-kuching-on-june-18/.
  • 15.Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data–from vision to reality. Euro Surveill. 2017;22(13):30494. doi: 10.2807/1560-7917.ES.2017.22.13.30494 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Gupta RK. Will SARS-CoV-2 variants of concern affect the promise of vaccines? Nat Rev Microbiol. 2021;21(6):340–1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Daniloski Z, Jordan TX, Ilmain JK, Guo X, Bhabha G, Sanjana NE. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. Elife. 2021;10:e65365. doi: 10.7554/eLife.65365 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Groves DC, Rowland-Jones SL, Angyal A. The D614G mutations in the SARS-CoV-2 spike protein: Implications for viral infectivity, disease severity and vaccine design. Biochem Biophys Res Commun. 2021;538:104–7. doi: 10.1016/j.bbrc.2020.10.109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Jackson CB, Zhang L, Farzan M, Choe H. Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. Biochem Biophys Res Commun. 2021;538:108–15. doi: 10.1016/j.bbrc.2020.11.026 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–27. doi: 10.1016/j.cell.2020.06.043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Plante JA, Liu Y, Liu J, Xia H, Johnson BA, Lokugamage KG, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116–21. doi: 10.1038/s41586-020-2895-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, et al. Structural and functional analysis of the D614G SARS-CoV-2 spike protein variant. Cell. 2020;183(3):739–51. doi: 10.1016/j.cell.2020.09.032 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zhang J, Cai Y, Xiao T, Lu J, Peng H, Sterling SM, et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science. 2021;372(6541):525–30. doi: 10.1126/science.abf2303 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Volz E, Hill V, McCrone JT, Price A, Jorgensen D, O’Toole Á, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64–75. doi: 10.1016/j.cell.2020.11.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yassim AS, Asras MF, Gazali AM, Marcial-Coba MS, Zainulabid UA, Ahmad HF. COVID-19 outbreak in Malaysia: Decoding D614G mutation of SARS-CoV-2 virus isolated from an asymptomatic case in Pahang. Mat Today Proc. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Zainulabid UA, Kamarudin N, Zulkifly AH, Gan HM, Tay DD, Siew SW, et al. Near-Complete Genome Sequences of Nine SARS-CoV-2 Strains Harboring the D614G Mutation in Malaysia. Microbiol. Resour. Announc. 2021;10(31):e00657–21. doi: 10.1128/MRA.00657-21 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Sievers F, Higgins DG. Clustal Omega for making accurate alignments of many protein sequences. Protein Science. 2018;27(1):135–45. doi: 10.1002/pro.3290 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Hall T. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. In: Nucleic Acids Symp Ser. 1999;41:95–98. [Google Scholar]
  • 29.Tamura K, Stecher G, Kumar S. MEGA11: molecular evolutionary genetics analysis version 11. Mol Biol Evol. 2021;38(7):3022–7. doi: 10.1093/molbev/msab120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol. 1987;4(4):406–25. doi: 10.1093/oxfordjournals.molbev.a040454 [DOI] [PubMed] [Google Scholar]
  • 31.Rodrigues CH, Myung Y, Pires DE, Ascher DB. mCSM-PPI2: predicting the effects of mutations on protein–protein interactions. Nucleic Acids Res. 2019;47(W1):W338–44. doi: 10.1093/nar/gkz383 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Pires DE, Rodrigues CH, Ascher DB. mCSM-membrane: predicting the effects of mutations on transmembrane proteins. Nucleic Acids Res. 2020;48(W1):W147–53. doi: 10.1093/nar/gkaa416 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Choi Y, Chan AP. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels. Bioinformatics. 2015;31(16):2745–7. doi: 10.1093/bioinformatics/btv195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Bromberg Y, Rost B. SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res. 2007; 35(11):3823–35. doi: 10.1093/nar/gkm238 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Elengoe A. COVID-19 outbreak in Malaysia. Osong Public Health Res Perspect. 2020;11(3):93. doi: 10.24171/j.phrp.2020.11.3.08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Chong YM, Sam IC, Chong J, Kahar Bador M, Ponnampalavanar S, Syed Omar SF, et al. SARS-CoV-2 lineage B. 6 was the major contributor to early pandemic transmission in Malaysia. PLoS Negl Trop Dis. 2020;14(11):e0008744. doi: 10.1371/journal.pntd.0008744 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Tan KK, Tan JY, Wong JE, Teoh BT, Tiong V, Abd-Jamil J, et al. Emergence of B. 1.524 (G) SARS-CoV-2 in Malaysia during the third COVID-19 epidemic wave. Sci Rep. 2021;11(1):1–2. doi: 10.1038/s41598-020-79139-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Sengupta A, Hassan SS, Choudhury PP. Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs. Infect Genet Evol. 2021;89:104724. doi: 10.1016/j.meegid.2021.104724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Chen Z, Chong KC, Wong MC, Boon SS, Huang J, Wang MH, et al. A global analysis of replacement of genetic variants of SARS-CoV-2 in association with containment capacity and changes in disease severity. Clin Microbiol Infect. 2021;27(5):750–7. doi: 10.1016/j.cmi.2021.01.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Allen H, Vusirikala A, Flannagan J, Twohig KA, Zaidi A, Chudasama D, et al. Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant (B. 1.617. 2): national case-control study. The Lancet Regional Health-Europe. 2021:100252. doi: 10.1016/j.lanepe.2021.100252 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B. 1.1. 7 in England. Science. 2021;372(6538). doi: 10.1126/science.abg3055 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592(7854):438–43. doi: 10.1038/s41586-021-03402-9 [DOI] [PubMed] [Google Scholar]
  • 43.Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. Update note on B. 1.1. 7 severity. https://www.gov.uk/government/publications/nervtag-update-note-on-b117-severity-11-february-2021/nervtag-update-note-on-b117-severity-11-february-2021
  • 44.Starr TN, Greaney AJ, Dingens AS, Bloom JD. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep. 2021;2(4):100255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. MedRxiv. 2021. [Google Scholar]
  • 46.Madhi SA, Baillie V, Cutland CL, Voysey M, Koen AL, Fairlie L, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant. N Eng J Med. 2021;384(20):1885–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Huang R, Rao H, Shang J, Chen H, Li J, Xie Q, et al. A cross-sectional assessment of health-related quality of life in Chinese patients with chronic hepatitis c virus infection with EQ-5D. Health Qual Life Outcomes. 2018;16(1):1–1. doi: 10.1186/s12955-017-0829-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7. Nature. 2021;593(7857):130–5. doi: 10.1038/s41586-021-03398-2 [DOI] [PubMed] [Google Scholar]
  • 49.Wu K, Werner AP, Moliva JI, Koch M, Choi A, Stewart-Jones GB, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. BioRxiv. 2021. doi: 10.1101/2021.01.25.427948 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Hamed SM, Elkhatib WF, Khairalla AS, Noreddin AM. Global dynamics of SARS-CoV-2 clades and their relation to COVID-19 epidemiology. Sci Rep. 2021;11(1):1–8. doi: 10.1038/s41598-020-79139-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Sengupta A, Hassan SS, Choudhury PP. Sengupta A, Hassan SS, Choudhury PP. Clade GR and clade GH isolates of SARS-CoV-2 in Asia show highest amount of SNPs. Infect Genet Evol. 2021;89:104724. doi: 10.1016/j.meegid.2021.104724 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Young BE, Wei WE, Fong SW, Mak TM, Anderson DE, Chan YH, et al. Association of SARS-CoV-2 clades with clinical, inflammatory and virologic outcomes: An observational study. EBioMedicine. 2021;66:103319. doi: 10.1016/j.ebiom.2021.103319 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Public Health Front. 2020;8:152. doi: 10.3389/fpubh.2020.00152 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nature Commun. 2020;11(1):1–0. doi: 10.1038/s41467-020-19741-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Ali F, Kasry A, Amin M. The new SARS-CoV-2 strain shows a stronger binding affinity to ACE2 due to N501Y mutant. Med Drug Discov. 2021;10:100086. doi: 10.1016/j.medidd.2021.100086 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Khan A, Zia T, Suleman M, Khan T, Ali SS, Abbasi AA, et al. Higher infectivity of the SARS‐CoV‐2 new variants is associated with K417N/T, E484K, and N501Y mutants: An insight from structural data. J Cell Physiol. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Nelson G, Buzko O, Spilman PR, Niazi K, Rabizadeh S, Soon-Shiong PR. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y. V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. BioRxiv. 2021. [Google Scholar]
  • 58.Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, et al. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution. Nature Microbiol. 2021;6(9):1188–98. doi: 10.1038/s41564-021-00954-4 [DOI] [PubMed] [Google Scholar]
  • 59.Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM et al. SARS-CoV-2 variants, spike mutations and immune escape. Nature Rev Microbiol. 202;19(7):409–24. doi: 10.1038/s41579-021-00573-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184(5):1171–87. doi: 10.1016/j.cell.2021.01.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.WHO: Tracking Variants of Concern: Available from: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
  • 62.Corver J, Broer R, Van Kasteren P, Spaan W. Mutagenesis of the transmembrane domain of the SARS coronavirus spike glycoprotein: refinement of the requirements for SARS coronavirus cell entry. Virol J. 2009;6(1):1–3. doi: 10.1186/1743-422X-6-230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727–34. doi: 10.1073/pnas.2003138117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Fu Q, Chou JJ. A trimeric hydrophobic zipper mediates the intramembrane assembly of SARS-CoV-2 spike. J Am Chem Soc. 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Geoghegan JL, Moreland NJ, Le Gros G, Ussher JE. New Zealand’s science-led response to the SARS-CoV-2 pandemic. Nature Immunol. 2021;22(3):262–3. doi: 10.1038/s41590-021-00872-x [DOI] [PubMed] [Google Scholar]
  • 66.Lane CR, Sherry NL, Porter AF, Duchene S, Horan K, Andersson P, et al. Genomics-informed responses in the elimination of COVID-19 in Victoria, Australia: an observational, genomic epidemiological study. Lancet Public Health. 2021;6(8):e547–56. doi: 10.1016/S2468-2667(21)00133-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Gozashti L, Corbett-Detig R. Shortcomings of SARS-CoV-2 genomic metadata. BMC Res Notes. 2021;14(1):1–4. doi: 10.1186/s13104-020-05413-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Ahmed S Abdel-Moneim

15 Oct 2021

PONE-D-21-25859Whole Genome Sequencing Analysis of Spike D614G Mutation Reveals Unique SARS-CoV-2 Lineages of B.1524 and AU.2 in MalaysiaPLOS ONE

Dear Dr. AHMAD,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 29 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Ahmed S. Abdel-Moneim, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

3. Please upload a new copy of Figure 2 as the detail is not clear. Please follow the link for more information: " ext-link-type="uri" xlink:type="simple">https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" " ext-link-type="uri" xlink:type="simple">https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/"

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Review Comments to the Author

Reviewer #1: General comment

Considering the large scarcity of sequences from this country (but not limited to), the work of Zainulabid et al, about SARS-CoV-2 molecular epidemiology in Malaysia, comes to contribute with CoV-2 genomic surveillance studies. The work is logically well conducted and written. Considering the SARS-CoV-2 spread flow for other countries vs the intense individuals movement across the globe, the work also adds novelty by inferring and discussing the new lineages circulating. Although this Referee feels the lack of time-scale trees to try establish the origin of these new strains, on the other hand, considering the current pandemic scenario, the work brings interesting and useful data for the scientific community.   

Minor concerns

Materials and Methods

Sample selection

Please, inform us the protocol used for detection of SARS-CoV-2

RNAs extraction

Line 123: Please, add the ct value.

Public database SARS-CoV-2 genome analysis

Line 149: Does the criteria of sequence selection have been based only on the length? What about the sequencing coverage? Please, add such information.

Results

- Could you please clarify the results from Table 3? It seems paradoxical.

- Please, improve the quality of all figures presented.

- Fig. 2. Phylogenetic trees provided are difficult to read.

- Fig. 2 C and D - please, provide the whole tree.

- Fig. 3: What is A and B? Where is the start and end position? It is confusing. The way it is, it does not add too much to the work.

- Fig. 4. same above (Fig. 3)

- Fig. 5. Did you mean Spike TM Domain?

Origin of the massive spread of COVID-19 cases in Pahang

- Sometimes it is difficult to understand what the authors are inferring because of the codes such as IIUM5763/2021. Maybe replacing it by the city(district)/year (code between parenthesis) would become easier to the readers. The same for the trees (tip label).

- Please, replace and add the WHO new nomenclatures for SARS-CoV-2 variants since it becomes easier to understand --- in the whole manuscript.

Discussion

Line 350: Please, use “our analysis of” instead of “our detailed analysis of”.

Line 358: add a reference

Line 358: same from line 350.

Line 436: Please, choose to use countries or cities.

Reviewer #2: The paper is well written and results are novel. However, some grammatical errors needs the attention e.g. line 63 had (has), line 203 were (was), line 249 is (was), line 250 is (was), line 306 was (is), line 340 was (are), line 383 follows (followed) etc. Another concern is that the sample size is small. Please justify it. Add mechanism underlying the mode of action of SARS-CoV-2 in causing the disease and symptoms.

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Feb 25;17(2):e0263678. doi: 10.1371/journal.pone.0263678.r002

Author response to Decision Letter 0


14 Dec 2021

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Thank you for providing the template. Our revised manuscript follows the journal guideline to the best of our understanding.

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Response: The data has been submitted to the GISAID public domain and accessible to all who wish to access. Accession numbers of sequences are also provided in the manuscript and in the phylogenetic analysis and figures.

3. Please upload a new copy of Figure 2 as the detail is not clear. Please follow the link for more information: https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/" https://blogs.plos.org/plos/2019/06/looking-good-tips-for-creating-your-plos-figures-graphics/"

Response: Figure 2 has been thoroughly revised for clarity and now represent more detailed and resolved information.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Response: We have thoroughly scanned the list of references and no such reference (retracted) was found. We have also transformed the references as per PLoS One format. Citations of all papers which were then in preprint and now published are accordingly modified.

Reviewers' comments:

Comments to the Author

Reviewer #1: General comment

Considering the large scarcity of sequences from this country (but not limited to), the work of Zainulabid et al, about SARS-CoV-2 molecular epidemiology in Malaysia, comes to contribute with CoV-2 genomic surveillance studies. The work is logically well conducted and written. Considering the SARS-CoV-2 spread flow for other countries vs the intense individuals movement across the globe, the work also adds novelty by inferring and discussing the new lineages circulating. Although this Referee feels the lack of time-scale trees to try establish the origin of these new strains, on the other hand, considering the current pandemic scenario, the work brings interesting and useful data for the scientific community.

Response: We are grateful for the reviewer suggestion and in the phylogenetic analysis presented in the revised manuscript we have address this observation.

Minor concerns

Materials and Methods

Sample selection

Comment: Please, inform us the protocol used for detection of SARS-CoV-2

Response: SARS-CoV-2 was detected through RT PCR and mentioned under Sample selection heading

RNAs extraction

Comment: Line 123: Please, add the ct value.

Response: Samples with less than 25 ct values were selected for the subsequent investigation and this information has also been provided in the revised manuscript.

Public database SARS-CoV-2 genome analysis

Comment: Line 149: Does the criteria of sequence selection have been based only on the length? What about the sequencing coverage? Please, add such information.

Response: Criteria of sequence selection has been elaborated and highlighted in the same section in the revised manuscript. “Sequences were selected based on completion of the genome with minimum number of unresolved nucleotides. Restraining the selection from the total of 1356 to 986 sequences”

Results

Comment: Could you please clarify the results from Table 3? It seems paradoxical.

Response: Table 3 shows the prediction of three different programs to suggest the potential impact of the mutations. Since all three programs based on different algorithms and used different base line data, it is possible, rather not very uncommon that they may end up giving different predictions for same mutation.

Comment: Please, improve the quality of all figures presented.

Fig. 2. Phylogenetic trees provided are difficult to read.

Fig. 2 C and D - please, provide the whole tree.

Response: Figure 2 has been thoroughly revised for clarity and now represent more detailed and resolved information. Phylogenetic tree with more pertinent sequences was reconstructed with Wuhan as an outgroup with relatively more statistical support of 1000 bootstraps (revised version) compared to 500 (previous version). Whole tree is also provided in MEGA format for the reference as supporting information.

Comment: Fig. 3: What is A and B? Where is the start and end position? It is confusing. The way it is, it does not add too much to the work.

Response: We are highly grateful and agree to the suggestion of the reviewer, since the information is already present in the text of the manuscript, we have removed the figure 3.

Comment: Fig. 4. same above (Fig. 3)

Response: We are highly indebted for the suggestion; Figure 4 has been modified for better clarity and respective legend of the figure elaborate the flow of the Figure 4 (previous version) and now Figure 3 (revised version). In the schematic diagram of spike protein N and C terminal are also labelled.

Comment: Fig. 5. Did you mean Spike TM Domain?

Response: Yes, full name is also used in the figure legend

Origin of the massive spread of COVID-19 cases in Pahang

Comment: Sometimes it is difficult to understand what the authors are inferring because of the codes such as IIUM5763/2021. Maybe replacing it by the city(district)/year (code between parenthesis) would become easier to the readers. The same for the trees (tip label).

Response: Indeed, this is an excellent suggestion and we have made two important changes in this regard.

1. In the revised manuscript and in the phylogenetic analysis figure (Fig 2) we have used GISAID accession number instead of sample code along with the geographical location of Pahang SARS-CoV-2 D614G variants.

2. In the revised manuscript we have also added the collection month and year of the Pahang SARS-CoV-2 D614G variants

Comment: Please, replace and add the WHO new nomenclatures for SARS-CoV-2 variants since it becomes easier to understand --- in the whole manuscript.

Response: In the revised manuscript WHO nomenclature is used where appropriate

Discussion

Comment: Line 350: Please, use “our analysis of” instead of “our detailed analysis of”.

Response: Modifications made

Comment: Line 358: add a reference

Response: Reference added

Comment: Line 358: same from line 350.

Response: Modifications made

Comment: Line 436: Please, choose to use countries or cities.

Response: We are grateful to the reviewer for the suggestion and modifications are made in the revised manuscript

Reviewer #2: The paper is well written and results are novel. However, some grammatical errors needs the attention e.g. line 63 had (has), line 203 were (was), line 249 is (was), line 250 is (was), line 306 was (is), line 340 was (are), line 383 follows (followed) etc.

Response: We are thankful to the reviewer for the suggestion and modifications are made in the revised manuscript

Comment: Another concern is that the sample size is small. Please justify it.

Response: Sample selection criteria has been explained in the methodology section of the revised manuscript.

Comment: Add mechanism underlying the mode of action of SARS-CoV-2 in causing the disease and symptoms.

Response: We are thankful to the reviewer for highlighting this, brief description regarding the SARS-CoV-2 mode of action has been added in the introduction.

Attachment

Submitted filename: Reponse to Reviewers.docx

Decision Letter 1

Ahmed S Abdel-Moneim

25 Jan 2022

Whole Genome Sequence Analysis Showing Unique SARS-CoV-2 Lineages of B.1.524 and AU.2 in Malaysia

PONE-D-21-25859R1

Dear Dr. AHMAD,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Ahmed S. Abdel-Moneim, Ph.D.

Academic Editor

PLOS ONE

Acceptance letter

Ahmed S Abdel-Moneim

18 Feb 2022

PONE-D-21-25859R1

Whole Genome Sequence Analysis Showing Unique SARS-CoV-2 Lineages of B.1.524 and AU.2 in Malaysia

Dear Dr. Ahmad:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Ahmed S. Abdel-Moneim

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. D614G variant lineage distribution in 2020 and 2021 based on complete genomes deposited to GISAID (Malaysia).

    A. The distribution of lineages from March to December, 2020. B. The distribution of lineages from January to July, 2020.

    (TIFF)

    S1 File. Selected (987) sequences from SARS-CoV-2 D614G variant from Malaysia including Wuhan SARS-CoV-2.

    (DOCX)

    S2 File. Complete phylogenetic tree in MEGA XI format.

    (MTSX)

    S1 Table. Collate metadata.

    (CSV)

    S2 Table. Summary of date and D614G variant virus strains from each lineage first detected in Malaysia.

    (PDF)

    Attachment

    Submitted filename: Reponse to Reviewers.docx

    Data Availability Statement

    All sequences data are available at https://trace.ncbi.nlm.nih.gov/Traces/sra/?study=SRP324679.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES